We compared the efficacy, toxicity, and cost of topotecan-filgrastim and filgrastim alone for mobilizing peripheral blood stem cells (PBSCs) in 24 consecutive pediatric patients with newly diagnosed medulloblastoma. PBSCs were mobilized with an upfront window of topotecan-filgrastim for 11 high-risk patients (residual tumor у1.5 cm 2 after resection; metastases limited to neuraxis) and with filgrastim alone for 13 average-risk patients. All patients subsequently underwent craniospinal irradiation and four courses of high-dose chemotherapy with stem cell rescue. Target yields of CD34 
malignancies. [1] [2] [3] [4] [5] Improvements in supportive care and increasing experience with stem-cell rescue after myeloablative chemotherapy have reduced the morbidity of highdose chemotherapy, and this reduction in morbidity has made such treatment applicable to a wide spectrum of diseases. 6 Peripheral blood stem cells (PBSCs) are increasingly used for rescue because of their engraftment characteristics and the ease with which they can be collected. 7, 8 Stem cells are usually mobilized into the peripheral blood in one of three ways: with cytokine therapy alone, with myelosuppressive chemotherapy alone or with a combination of both. 9 The present standard of care uses filgrastim (G-CSF) or sargramostim (GM-CSF) to mobilize PBSCs, but these agents may not mobilize a sufficient number of stem cells in as many as 67% of patients. [10] [11] [12] For these patients, alternative mobilization regimens are needed. 10, 13 The choice of regimen to enhance mobilization, particularly for children, is important because of the potential increased toxicity of chemotherapy-based mobilization and because of the need for additional apheresis procedures and marrow backups required with regimens using cytokines alone. Therefore, it is imperative to evaluate the economic and therapeutic impact of any new mobilizing regimen to determine its usefulness. 14 Topotecan, a new topoisomerase I inhibitor with prominent activity 15 against many malignancies in pediatric and adult patients, is being evaluated in several new treatment regimens for various tumors. [16] [17] [18] [19] Our aim was to compare the efficacy, toxicity, and relative costs of intravenously administered topotecan and filgrastim and of filgrastim alone in mobilizing PBSCs. This retrospective observational study was part of our institutional medulloblastoma/primitive neuroectodermal tumor (PNET) protocol.
Patients and methods

Patients
Patient eligibility criteria and definitions of average-risk and high-risk disease have been previously reported. 20 The protocol was approved by the Institutional Review Board.
Signed informed consent was obtained from parents or legal guardians, as appropriate, before protocol therapy was initiated.
Study design
Patients with average-risk disease received intravenously (i.v.) administered filgrastim (Neupogen; Amgen, Thousand Oaks, CA, USA) at a dose of 10 g/kg daily 21 until the absolute peripheral CD34
+ cell count was at least 20/l. PBSC harvesting then began and continued until the target yield of 8 ϫ 10 6 CD34 + cells/kg was obtained or until the absolute peripheral CD34
+ cell count dropped below 20/l. Because of patient tolerance, the maximum number of apheresis procedures per patient was prospectively limited to three. The patients subsequently underwent craniospinal irradiation over a period of 6 weeks, followed by a 6-week rest period. Patients then received four courses of high-dose chemotherapy; each course was followed by reinfusion of at least 2 ϫ 10 6 autologous CD34 + cells per kg ( Figure 1 ).
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Patients with high-risk disease were given two cycles of outpatient chemotherapy consisting of topotecan (5.5 mg/m 2 daily as an i.v. infusion for 5 days every 21 days). The day 1 topotecan dosage was 5.5 mg/m 2 , and subsequent doses were adjusted to maintain the target topotecan lactone area under the plasma concentration-time curve (AUC) between 120 and 160 ng/ml/h. Twenty-four hours after the last dose of topotecan, patients received i.v. filgrastim (10 g/kg per day) until the absolute peripheral CD34 + cell concentration was at least 20/l. Daily peripheral CD34 + cell counts began on day 1 of filgrastim administration for the first four patients in the topotecan-filgrastim mobilization. Because the initial four patients who received topotecan and filgrastim did not have measurable CD34
+ cell counts before day 4, the CD34 + cell counts for the remaining patients were obtained when the leukocyte count exceeded 1.0 ϫ 10 9 /l or after day 3 of filgrastim administration. Guidelines for harvesting PBSCs were similar to those of the average-risk group. After PBSCs were collected, the patients in the high-risk group were given a second course of topotecan followed by craniospinal irradiation, a 6-week rest period, and four courses of highdose chemotherapy and PBSC rescue that were identical to those given to patients with average-risk disease (Figure 1 ). Although the chemotherapy regimen was not myeloablative, PBSC rescue was performed after each course of chemotherapy, so that the dose intensity of the regimen could be maintained. 20 In either group, if the target cell yield was not obtained, bone marrow was harvested from the iliac bone or PBSC harvest was repeated, either before or after radiotherapy. The target dose of marrow cells required for each cycle of high-dose chemotherapy was 1 ϫ 10 8 nucleated cells per kg.
Flow cytometric studies
The CD34
+ cell count was measured by using the FACSCalibur Flow Cytometry System (BD Biosciences, San Jose, CA, USA) and three-color direct immunofluorescence. The following antibodies were used: phycoerythrin (PE)-labeled anti-CD34 monoclonal antibody (CD34-PE; BD Biosciences), PerCP-labeled anti-CD45 antibody (CD45-PerCP; BD Biosciences), and fluorescein isothiocyanate (FITC)-labeled anti-CD3 antibody (CD3-FITC; DAKO Corporation, Carpinteria, CA, USA). Briefly, 50 l of diluted whole blood from each patient was mixed with 50 l of Dulbecco's phosphate-buffered saline (BioWhittaker, Walkersville, MD, USA), 1% human serum albumin, 0.1% sodium azide, and 10 l of each antiserum (CD45-PerCP, CD3-FITC, and CD34-PE). A control sample was analyzed with PE-labeled and FITC-labeled mouse IgG 1 and CD45-PerCP. The mixtures were incubated in the dark at room temperature for 10 min and erythrocytes were subsequently lysed with FACSLyse (BD Biosciences). Each sample was then washed twice before 10 5 to 10 6 cells from each sample were analyzed.
Peripheral and marrow stem-cell harvest
PBSCs were harvested by using COBE Spectra (COBE, Lakewood, CO, USA) apheresis machines. The total blood volume (each blood volume was assumed to be 75 ml/kg of body weight) from each patient was processed three times. On the day before PBSC harvest (ie the day on which the absolute peripheral CD34
+ cell count was predicted to be greater than 20/l), a 5-French single-lumen central venous catheter (Cook, Bloomington, IN, USA) was inserted into the femoral vein of those patients without adequate peripheral venous access. The catheter was left in place for the duration of apheresis and was removed after the last apheresis procedure of the mobilization cycle.
Anticoagulation was achieved by adding acid-citratedextrose (ACD); the ratio of blood to ACD was 15:1. Blood flow was dependent on the draw line and did not exceed 15 ml/kg/min. The maximum rate of ACD was 1 ml/kg/min. No calcium replacement was given unless symptomatic hypocalcemia occurred.
Patient monitoring
During mobilization, complete blood counts (CBCs) and absolute peripheral blood CD34 + cell counts were performed daily. Patients were monitored for signs of toxicity as defined by Version 2 of National Cancer Institute (NCI) common toxicity criteria. Blood chemistry values were evaluated twice a week or when clinically appropriate.
Storage and reinfusion of stem cells
Stem cells underwent no manipulation and were stored in a final concentration of 10% dimethyl sulfoxide diluted with autologous plasma or 5% human serum albumin according to standard procedures. Stem cells were thawed at the bedside, and the unmanipulated cells were transfused by slow intravenous push over a period of 10 to 30 min.
Supportive care
After stem-cell infusion patients were discharged and treated in the outpatient setting. Filgrastim (5 g/kg) was administered intravenously to all patients 24 h after rein- fusion of peripheral or marrow stem cells. Filgrastim was given for at least 7 days or until the ANC was at least 2.0 ϫ 10 9 /l for 2 consecutive days after the expected nadir. Blood products were given to maintain normal platelet counts (at least 30 ϫ 10 9 /l) and hematocrit concentrations (at least 20%). If febrile neutropenia (temperature Ͼ38°C; ANC Ͻ0.5 ϫ 10 9 /l) developed, patients were admitted and given broad-spectrum antibiotics intravenously.
Measurement of topotecan lactone AUC and dose adjustments
The topotecan dose for each patient was adjusted on the basis of plasma levels obtained during each course to attain a single-day topotecan lactone AUC of 140 Ϯ 20 ng/ml/h.
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To determine the topotecan systemic exposure in each patient, plasma samples were collected before topotecan infusion and at serial times after the end of the infusion. Topotecan lactone AUC was measured by using an isocratic high-performance liquid chromatography assay with fluorescence detection. 23 A two-compartment model was fitted to the topotecan lactone plasma and concentrationtime data by using a maximum a posteriori Bayesian algorithm as implemented in ADAPT II. 24 The model parameters for each patient were used to determine the appropriate topotecan dose to attain the target range.
Cost analysis
We performed a cost-minimization analysis 14, 25 of the total cost of high-dose chemotherapy to determine whether the higher initial cost of the topotecan-filgrastim mobilization regimen (as compared with filgrastim alone) was offset by cost savings brought about by reduced use of resources during the mobilization and collection of PBSCs and the initial post-transplantation hospitalization period. A provider (ie hospital) perspective was used in the analysis. Resource units for important health care resources were collected by medical chart review and were converted to costs. Drug cost was based on actual acquisition cost in 1999, normalized to an adult surface area of 1.73 m 2 to facilitate comparison with findings from adult studies. The cost of hospitalization and transfusions was based on actual costs at St Jude Children's Research Hospital in 1999. For PBSC and bone marrow harvests, we used the cost estimates from the time and motion study of Glaspy et al. 26 The analysis was made by using an intent-to-treat method for each arm.
Hematologic endpoints
The primary end point of the study was the mobilization of the target yield of CD34 + cells (8 ϫ 10 6 /kg). Failure to achieve the target yield significantly affected the administration of high-dose chemotherapy and constituted primary failure.
The secondary endpoints were the number of platelet transfusions required and the time required for the engraftment of platelets and neutrophils. The time to platelet engraftment was defined as the number of days from the day of stem-cell infusion to the first day of a period of 7 consecutive days during which the platelet count was at least 20 ϫ 10 9 /l without platelet support. The time to neutrophil engraftment was defined as the number of days from the day of stem cell infusion to the first of 3 consecutive days after the chemotherapy-induced nadir during which the ANC was at least 0.5 ϫ 10 9 /l.
Statistical methods
Fisher's exact test 27 was used as a test of equality of proportions of patients in the treatment groups whose PBSCs were mobilized. Mixed-model analyses of repeated measures 28 data estimated the absolute CD34 + cell count during the period of filgrastim administration. The exact log-rank test 29 was used to determine whether the percentage of patients in whom neutrophil and platelet engraftment was achieved differed after each cycle of high-dose chemotherapy. Kaplan-Meier estimates 30 in each group (by cycle of high-dose chemotherapy) were obtained for the percentages of patients in whom neutrophil and platelet engraftment was achieved. The Wilcoxon rank-sum test 31 was used to compare (by cycle) the number of platelet transfusions and the number of red blood cell transfusions between the two treatment groups.
Results
Patient characteristics
Thirty-four patients with medulloblastoma were treated at St Jude Children's Research Hospital between October 1996 to September 1999. Ten patients did not qualify for this mobilization study: seven had an ECOG performance status of 4 (six had posterior fossa syndrome; one was blind after surgery), and three required immediate radiotherapy (one had spinal metastases and paraparesis and two had to begin radiotherapy to comply with protocol timing). A total of 24 patients were enrolled prospectively on the protocol. The results of follow-up that are reported here include those up to 31 October 1999.
Eleven patients with high-risk disease were enrolled on the topotecan-filgrastim arm; 13 patients with average-risk disease were enrolled on the filgrastim arm (Table 1) . One patient on the filgrastim arm was subsequently found to have medulloblastoma cells in the CSF. However, this patient was included on the filgrastim arm because his PBSCs had already been mobilized with filgrastim.
Topotecan levels and dosage
The median topotecan dose used in this study was 5.0 mg/m 2 per day (range, 2.0-8.0 mg/m 2 per day). These doses are higher than the published maximum tolerated dose for this schedule (ie 2.0 mg/m 2 per day), 32 because we performed dosage adjustments for each patient to attain a topotecan lactone AUC of 140 Ϯ 20 ng/ml/h. The median AUC was 143.7 ng/ml/h (range, 30.1-367.2 ng/ml/h).
PBSC mobilization by filgrastim
We attempted to mobilize the PBSCs of the 13 patients with average-risk disease by using filgrastim alone; the target yield of CD34 + cells was obtained from only six patients (46%). The target yield was achieved with 1 day of PBSC harvest from only one patient, with 2 days of PBSC harvest from four patients, and with 3 days of PBSC harvest from one patient. PBSCs failed to mobilize in four of the seven remaining patients; the peak peripheral CD34 + cell counts of two patients were less than 20/l, and the counts of two other patients peaked on study day 4 and rapidly declined to less than 20/l on the following day. The peripheral CD34
+ cell counts of the other three patients were more than 20/l, but the target yield of CD34 + cells was not obtained after 2 to 3 days of harvest. Despite additional bone marrow and PBSC harvests, the total yield of stem cells from three of these seven patients was insufficient. Therefore, the dose of chemotherapy during the last course for one patient was reduced by 25%, and no stem cell rescue was performed for these three patients.
The median day on which the first PBSCs could be harvested from the patients on the filgrastim arm (n = 6) was study day 6 (range, days 4 to 6). PBSC harvest was completed within 5 days (range, days 4 to 8). The median peak count of peripheral CD34
+ cells for patients on the filgrastim arm was 54/l (range, 6-69/l). The median total yield of CD34 + cells from the first PBSC harvest was 3.7 ϫ 10 6 /kg (range, 0-21.5 ϫ 10 6 /kg), whereas the median yield of the second PBSC harvest was 3.2 ϫ 10 6 /kg (range, 0-5.0 ϫ 10 6 /kg). 
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PBSC mobilization by topotecan-filgrastim
In contrast to the low percentage of patients (46%) whose PBSCs were mobilized by treatment with filgrastim alone, 100% of patients who had high-risk disease and were treated with a combination of topotecan and filgrastim experienced successful PBSC mobilization (P = 0.0059).
The target yield of CD34 + cells in patients treated with topotecan and filgrastim was achieved with a single apheresis procedure. The median day to apheresis was study day 9 (range, day 7 to day 10). The median peak of peripheral blood CD34
+ cells was 328/l (range, 54 to 495/l). The mean total yield of CD34 + cells 21.5 ϫ 10 6 /kg (range, 12.9-72 ϫ 10 6 /kg), which was six-fold greater than that of patients treated with filgrastim alone (3.7 ϫ 10 6 /kg).
Engraftment
By the end of October 1999, 13 patients in the filgrastim group and nine patients in the topotecan-filgrastim group had completed a total of 72 courses of high-dose chemotherapy with PBSC rescue. PBSCs had been mobilized in two patients on the topotecan-filgrastim arm, but these patients had not yet undergone stem cell transplantation at the time that this PBSC mobilization study was closed for analysis. The median times required for neutrophil engraftment and for platelet engraftment in patients in the topotecanfilgrastim group after each course of chemotherapy were similar to those of patients in the filgrastim group (data not shown). The paper describing the overall feasibility of this protocol has recently been published. 20 
Toxicity associated with mobilization
The administration of filgrastim was well tolerated without any significant toxicity. Topotecan-induced grade 2 fever (temperature between 38.1°C and 40°C) occurred in four patients (36%) during infusion ( Table 2 ) and lasted an average of 4 days (range, 3 to 5 days). Results of blood cultures were negative for all patients during these febrile periods attributed to topotecan administration.
The only grade 4 toxicity in the topotecan-filgrastim group was related to myelosuppression; all episodes were short and uncomplicated. Five patients (45%) had leukocyte counts lower than 1.0 ϫ 10 9 /l, and seven (64%) had ANCs less than 0.5 ϫ 10 9 /l. The median duration of grade 4 leu- kopenia was 5 days (range, 1-13 days), whereas that of neutropenia was 6 days (range, 2-8 days). Febrile neutropenia developed in four patients, and each of the four were treated with intravenously administered antibiotics for a median of 4 days (range, 3-5 days). The results of blood cultures were positive for only one patient with febrile neutropenia; in the peripheral blood culture grew a mixture of Staphylococcus saprophyticus and Corynebacterium spp., which were probably contaminants from the skin. No patient treated with topotecan-filgrastim experienced grade 3 or 4 mucositis or grade 3 or 4 toxicity involving the liver, kidney, or central nervous system (CNS). Moreover, we observed no fatal complications that were related to topotecan therapy.
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Cost analysis
The cost of mobilizing PBSCs with topotecan-filgrastim was $17 818 per patient, whereas that of mobilizing PBSCs with filgrastim alone was $12 710 per patient. The higher cost of topotecan-filgrastim mobilization is mainly attributed to the high cost of topotecan. This higher cost is offset, however, by the decreased use of resources in the topotecan-filgrastim group after high-dose chemotherapy and stem-cell infusion: the result was a saving of $9074 per patient after the stem cell infusion phase (Table 3) . Thus, the use of topotecan-filgrastim resulted in an overall saving of $3966 per patient.
Discussion
In a homogenous population of chemotherapy-naive patients with normal marrow function, we directly compared the efficacy of topotecan-filgrastim with that of filgrastim alone in mobilizing PBSCs. Findings of many stem cell mobilization studies are confounded by various factors (eg extensive prior therapy, marrow disease, and differ- ences in diagnosis) 33, 34 that make it difficult to draw valid conclusions about the efficacy of various mobilization regimens. The only difference between the two groups in our study was the presence or absence of neuraxis dissemination, which was unlikely to interfere with PBSC mobilization.
The recommended number of CD34 + cells for autologous transplantation has been increased from 2 ϫ 10 6 /kg to at least 5 ϫ 10 6 /kg. 35, 36 In recent studies 33, 35 in which the target total yield of CD34
+ cells was at least 5 ϫ 10 6 /kg, only 33% to 50% of the patients treated with filgrastim alone for PBSC mobilization achieved the target yield. Similarly, mobilization of stem cells for patients in our filgrastim group was poor (PBSCs were successfully mobilized in only 46% of patients) in part because our study design required a high target yield of CD34
+ cells (at least 8 ϫ 10 6 /kg). This requirement was necessary because stem cell rescue was performed after each course of high-dose chemotherapy (CD34 + cell dose given after each course, 2 ϫ 10 6 /kg). This feature highlights the failure of filgrastim alone in mobilizing sufficient stem cells for as many as 67% of patients 11, 33, 35 and the need of a more efficient mobilization regimen. 10, 13 We used a higher dose of topotecan (median dose, 5.0 mg/m 2 per day) than has been previously reported in the literature. 15, 16 We chose to use this pharmacokinetically guided dosing approach for topotecan on the basis of our preclinical 37 and clinical data. 23 This topotecan dosage and the resultant high level of systemic exposure to topotecan lactone were remarkably well tolerated with acceptable myelotoxicity. Determining whether a lower dose of topotecan is equally efficacious and reduces costs will require further study.
Although chemotherapy-based mobilization regimens are often complicated by infection, 9 the topotecan-filgrastim combination was well tolerated with manageable toxicity. The only grade 4 toxicity was related to myelosuppression: the ANCs of 64% of our patients were less than 0.5 ϫ 10 9 /l (median duration, 6 days). Febrile neutropenia occurred in only four patients (36%). This finding compares favorably with those of studies of high-dose cyclophosphamide 38 and of other chemotherapy-filgrastim mobilization regimens; [39] [40] [41] in those reports rates of febrile neutropenia ranged from 20% to 100%.
Scheduling the optimal time for PBSC harvest is difficult because the time at which the number of CD34
+ cells peaks after chemotherapy-based mobilization is unpredictable. 9 This lack of predictability is especially problematic in busy centers in which apheresis machines are used both for stem cell mobilization and platelet apheresis. The use of the topotecan-filgrastim combination resulted in a predictable pattern of PBSC mobilization. Time to mobilization in the topotecan-filgrastim-treated patients (study days 7 to 10) was as predictable as that in patients treated with filgrastim alone (study days 4 to 6). Planning was easier because one harvest was required to obtain target yields; in contrast, a mean of 2.3 apheresis procedures and bone marrow harvests were needed for those whose PBSCs failed to mobilize after treatment with filgrastim alone. This finding reflects the general clinical experience that mobilization with filgrastim alone results in the need for multiple apheresis procedures and additional bone marrow harvesting to obtain sufficient numbers of stem cells. 13 The increasing demand for greater numbers of stem cells for autologous transplantation may require the development of newer methods for enhancing PBSC mobilization, such as myelosuppressive therapy with filgrastim, as in our study, or treatment with a combination of cytokines.
Stem cells mobilized by the topotecan-filgrastim combination rapidly restored marrow function and allowed highdose chemotherapy to be administered as scheduled. Although the patients in the topotecan-filgrastim group received higher doses of spinal irradiation (36 to 39 Gy) than those in the filgrastim group (23.4 Gy) before highdose chemotherapy, the mean numbers of transfusions of platelets and red blood cells per patient were similar for both groups, and platelet and neutrophil engraftment also occurred at approximately the same time in both groups. Our findings are supported by those of Ferari et al who showed that topotecan followed by filgrastim and erythropoietin treatment mobilized high-quality stem cells as documented by flow-cytometric parameters with low apoptotic features. 42 
Contamination of the graft by tumor cells is thought to
Bone Marrow Transplantation contribute to an increased risk of relapse after autologous stem cell transplantation. 43 In peripheral blood, stem cells are mobilized more rapidly (days 1 and 2 of recovery) than tumor cells (days 5 and 6). 44 Kahn et al 45 reported that in a group of patients with breast cancer, 5.4% of PBSC products obtained during the first apheresis procedure were contaminated with tumor cells; during the second apheresis procedure, 15.4% were contaminated; and during the fourth and subsequent procedures, 42% were contaminated. Thus, it is postulated that to reduce the risk of contamination with tumor cells, it is crucial to obtain sufficient CD34 + cells from early apheresis procedures alone. This criterion appeared to be met when we used topotecan-filgrastim as a mobilizing agent. Thus, topotecan-filgrastim administration may result in grafts with less contamination by tumor cells.
Reduced hospitalization stay and the consequent use of fewer resources offset the additional cost of adding topotecan to filgrastim mobilization. The mean saving for the topotecan-filgrastim group was $3966 per patient. This finding supports the cost saving of the topotecan-filgrastim combination in PBSC mobilization, at least in the context of tandem transplantation.
On the basis of our findings, we conclude that the combination of topotecan and filgrastim is an efficacious, minimally toxic and cost-saving method for mobilizing PBSCs in pediatric patients with medulloblastoma enrolled on our trial in which stem-cell rescue was required after each course of chemotherapy. This combination may warrant testing in patients with other disease entities.
